13887-98-4

Basic information

• Product Name: 3,6,9-TRIOXAUNDECANEDIOIC ACID
• Synonyms: O,O'-OXYDIETHYLENE-DIGLYCOLIC ACID;TUDS;2,2'-[oxybis(2,1-ethanediyloxy)]bisacetic acid;TRIOXAUNDECANEDIOIC ACID;3,6,9-Trioxaundecanedioic acid (TUDS);Acetic acid, 2,2-oxybis(2,1-ethanediyloxy)bis-;2,2′-(Oxybis(2,1-ethandiyloxy))bisessigsure;3,6,9-Trioxa-1,11-undecanedioic acid
• CAS NO: 13887-98-4
• Molecular Formula: C₈H₁₄O₇
• Molecular Weight: 222.19
• EINECS: 237-655-9
• Product Categories: Heterocyclic Compounds
• Mol File: 13887-98-4.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 443.7 °C at 760 mmHg
• Flash Point: 178.3 °C
• Appearance: /
• Density: 1.3 g/mL at 20 °C(lit.)
• Vapor Pressure: 4.1E-09mmHg at 25°C
• Refractive Index: n20/D 1.470(lit.)
• Storage Temp.: Store below +30°C.
• Solubility: Soluble in Water, DMSO, DCM, DMF
• PKA: 3.09±0.10(Predicted)
• BRN: 1962084
• CAS DataBase Reference: 3,6,9-TRIOXAUNDECANEDIOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3,6,9-TRIOXAUNDECANEDIOIC ACID(13887-98-4)
• EPA Substance Registry System: 3,6,9-TRIOXAUNDECANEDIOIC ACID(13887-98-4)

Safety Data

• Hazard Codes: Xi
• Statements: 41
• Safety Statements: 26-39
• RIDADR: 1760
• WGK Germany: 1
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 13887-98-4(Hazardous Substances Data)

Usage

Description

PEG3-(CH2CO2H)2 is a PEG linker containing two terminal carboxylic acid groups. The hydrophilic PEG spacer increases solubility in aqueous media. The terminal carboxylic acids can react with primary amine groups in the presence of activators (e.g. EDC, or HATU) to form a stable amide bond.

Flammability and Explosibility

Notclassified

InChI:InChI=1/C8H14O7/c9-7(10)5-14-3-1-13-2-4-15-6-8(11)12/h1-6H2,(H,9,10)(H,11,12)

Upstream product

• 112-60-7 Tetraethylene glycol 
• 211746-77-9 di-tert-butyl 2,2’-(2,2’-oxybis(ethane-1,2-diyl)bis(oxy))diacetate 
• 79-11-8 chloroacetic acid 
• 111-46-6 diethylene glycol 

Downstream Products

• 31255-25-1 tetra-glycolic acid dichloride 
• 146773-32-2 2-[2-[2-(2-benzyloxy-2-oxo-ethoxy)ethoxy]ethoxy]acetic acid 
• 1612221-37-0 C₃₈H₅₆N₂O₉ 
• 1232884-92-2 C₃₇H₄₆O₉ 
• 1232884-88-6 ST₅₅₈₇ 
• 1365543-84-5 (R)-4-((4-(2,2-diphenylacetamido)-1-(4-hydroxyphenyl)-9-imino-3,11,18,28,34-pentaoxo-20,23,26-trioxa-2,8,10,12,17,29,33-heptaazahexatriacontan-36-yl)(methyl)amino)pyridinium 2,2,2-trifluoroacetate 
• 883564-93-0 13,13-dimethyl-11-oxo-3,6,9,12-tetraoxatetradecan-1-oic acid 
• 638212-99-4 {2-[2-({4-[3-[3-(4-fluoro-phenyl)-3-hydroxy-propyl]-2-(4-methoxy-phenyl)-4-oxo-azetidin-1-yl]-benzylcarbamoyl}-methoxy)-ethoxy]-ethoxy}-acetic acid 
• 41775-36-4 1,4,7,13-tetraoxa-10,16-diazacyclooctadecane 
• 84293-32-3 (S)-2-[2-(2-{2-[((S)-1-Carboxy-2-phenyl-ethylcarbamoyl)-methoxy]-ethoxy}-ethoxy)-acetylamino]-3-phenyl-propionic acid 
• 84308-20-3 (S)-2-[2-(2-{2-[((S)-1-Benzyloxycarbonyl-2-phenyl-ethylcarbamoyl)-methoxy]-ethoxy}-ethoxy)-acetylamino]-3-phenyl-propionic acid benzyl ester 
• 31250-00-7 N,N'-bisphenyl-3,6,9-trioxaundecanedicarboxamide 

Relevant articles and documents

Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma

We here report the synthesis of ethylene glycol N-interlinked imipramine dimers of various lengths from the tricyclic antidepressant desipramine via an amide coupling reaction followed by reduction with lithium aluminium hydride. The target molecules were found to be potent inhibitors of cellular viability while inducing cell type specific death mechanisms in three cancer cell lines including a highly chemoresistant Burkitt's lymphoma cell line. Basic amine analogues were found to be important for increased potency. Imipramine and desipramine were also tested for apoptotic activity and were found to be much less active than the novel dimeric compounds. Imipramine dimers were only found to be moderate inhibitors of the human serotonin transporter (hSERT) having IC50 values in the micromolar region whilst the induction of cell death occurred independently of hSERT expression. These results demonstrate the potential of newly designed and synthesised imipramines derivatives for use against malignant cells, including those resistant to standard chemotherapy.

Ether acid cobalt complex single crystal and preparation method as well as application thereof

The invention discloses ether acid cobalt complex single crystal, having a structure of [Co(L)(H2O)], wherein L is equal to di-ethoxy di-acetic acid. The invention also discloses a preparation method of the single crystal. According to the preparation method, a normal temperature volatilization method is adopted, i.e., L and Co(Ac)2.H2O are stirred in water for half an hour, and then are filtered, and filtrate is volatilized at normal temperature for two weeks, thus obtaining red blocky crystal suitable for X-ray single crystal diffraction, wherein the mol ratio of Co(Ac)2.H2O is 1 to 1. The invention further discloses application of the ether acid cobalt complex single crystal as a potential fluorescent material in detection on the adsorption quantity of a dye or an illuminating agent.

CHIRAL AMINOACID CONTAINING ACYCLIC LIGANDS-I. SYNTHESES AND CONFORMATIONS

Synthesis and spectral properties of optically active acyclic ligands, containing two (S)-phenylalanine residues (3a-f) are described.The synthesis is achieved by two different routes.Conformational studies in different solvents are performed by dilution and temperature-dependent experiments of 1H and 13C NMR spectroscopy.